Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome

Clin Infect Dis. 2003 May 1;36(9):e100-6. doi: 10.1086/374666. Epub 2003 Apr 22.


Three cases of chronic fatigue syndrome (CFS) that followed acute parvovirus B19 infection were treated with a 5-day course of intravenous immunoglobulin (IVIG; 400 mg/kg per day), the only specific treatment for parvovirus B19 infection. We examined the influence of IVIG treatment on the production of cytokines and chemokines in individuals with CFS due to parvovirus B19. IVIG therapy led to clearance of parvovirus B19 viremia, resolution of symptoms, and improvement in physical and functional ability in all patients, as well as resolution of cytokine dysregulation.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Fatigue Syndrome, Chronic / therapy*
  • Fatigue Syndrome, Chronic / virology
  • Female
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Male
  • Middle Aged
  • Parvoviridae Infections / therapy*
  • Parvovirus B19, Human / immunology*
  • Treatment Outcome


  • Immunoglobulins, Intravenous